Mirdametinib in Histiocytic Disorders
A phase 2 trial of Mirdametinib in Langerhans cell histiocytosis and Erdheim-Chester disease, Rosai-Dorfman disease and other histiocytic neoplasms, run by Children's Hospital Medical Center, Cincinnati, now recruiting.
Overview
Mirdametinib in Histiocytic Disorders is a phase 2 interventional study registered as NCT06153173 by Children's Hospital Medical Center, Cincinnati, with 40 participants planned, started 2024-02-05 and due to reach its primary completion in 2030-03. Interventions recorded: Mirdametinib. Conditions recorded: Langerhans Cell Histiocytosis (LCH), Juvenile Xanthogranuloma (JXG), Rosai-Dorfman Disease (RDD), Histiocytic Disorders.
Linked to the drug Mirdametinib because the registry names it among its interventions and Langerhans cell histiocytosis and Erdheim-Chester disease, Rosai-Dorfman disease and other histiocytic neoplasms among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialTesting the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia
Shares Mirdametinib and the tag pipeline.
- TrialMirdametinib in Patients With Advanced NF1-mutant Melanoma
Shares Mirdametinib and the tag pipeline.
- TrialLCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
Shares Langerhans cell histiocytosis (LCH) and the tag pipeline.
- InstitutionHistiocyte Society
Shares Langerhans cell histiocytosis (LCH), Erdheim-Chester disease, Rosai-Dorfman disease and other histiocytic neoplasms.
- TreatmentCladribine
Shares Langerhans cell histiocytosis (LCH), Erdheim-Chester disease, Rosai-Dorfman disease and other histiocytic neoplasms.
- TreatmentVemurafenib
Shares Langerhans cell histiocytosis (LCH), Erdheim-Chester disease, Rosai-Dorfman disease and other histiocytic neoplasms.
- TreatmentDabrafenib + trametinib
Shares Langerhans cell histiocytosis (LCH), Erdheim-Chester disease, Rosai-Dorfman disease and other histiocytic neoplasms.